Ontology highlight
ABSTRACT:
SUBMITTER: Jain RK
PROVIDER: S-EPMC7494003 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
Jain Rohit K RK Skelton William Paul WP Zhang Jingsong J
Cancer management and research 20200911
Enfortumab vedotin (EV) is an antibody-drug conjugate with humanized anti-Nectin-4 antibody linked with a microtubule-disrupting agent called monomethyl auristatin E. Nectin-4 is a cellular adhesion protein that is overexpressed in urothelial cancer. EV was approved in December 2019 for patients with locally advanced or metastatic urothelial cancer who previously received platinum-based chemotherapy and immune checkpoint inhibitors. Here, we reviewed the clinical efficacy and safety data that le ...[more]